Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Immunotherapy, and Lipid Transport Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TMEM30A (CDC50A) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TMEM30A ECD-Fc / Mutant Protein or Full-Length Lentivirus Premade Particles; high purity (>95%), endotoxin <1 EU/μg, sequence verified, 7-TM native conformation (NM_018247). | View TMEM30A Products |
| Gene Delivery | TMEM30A Promise-ORF / Lentivirus or Promise-ORF Clone; codon-optimized for mammalian expression, ideal for stable cell line generation and flow cytometry. | View TMEM30A Products |
| Benchmark Ab | Anti-TMEM30A recombinant antibody; sequence verified, chimeric human-mouse format, theoretical MW confirmed. | View TMEM30A Products |
| Validator | TMEM30A siRNA validation set; three unique sequences targeting distinct exons for high-specificity knockdown controls. | View TMEM30A Products |
| Related Target A | ATP8B1 – Critical P4-ATPase catalytic subunit that forms a flippase complex with TMEM30A. | View ATP8B1 Products |
| Related Target B | ATP11A – P4-ATPase catalytic alpha subunit; obligate functional binding partner in lipid flippase complex. | View ATP11A Products |
| Related Target C | TMEM30B (CCDC16B) – Paralog family member; essential for off-target liability counter-screening. | View TMEM30B Products |
| Related Target D | CD47 – Synergistic macrophage "don't eat me" signal target for combination immunotherapy. | View CD47 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Conformation (7-TM Topology & Native Glycosylation) | Lentivirus-mediated stable expression in HEK293 preserves native membrane orientation, post-translational modifications, and authentic antibody binding. |
| Target Specificity (Subfamily Off-target & Paralog Cross-reactivity) | Sequence verified, theoretical MW confirmed products for accurate cross-reactivity profiling; family-specific siRNA panels for TMEM30B counter-screen. |
| Lack of Positive Controls | Recombinant benchmark antibodies included for assay standardization, flow cytometry controls, and internalization tracking. |
| False Positives in Phospholipid Flipping Assays | Endotoxin controlled (<1 EU/μg) and validated siRNA included for stringent specificity checks. |
| Flippase Complex Activity Validation | Co-expression systems with ATP11A/ATP8B1 available; high-purity reagents for phospholipid transport mechanism studies. |
| Cross-species (Cyno/Mouse/Human) Translation | Ortholog-specific ORF clones (human, cyno, mouse); sequence verified with conserved epitope mapping for toxicology bridging. |
| Cell Surface Accessibility Confirmation | Flow cytometry grade lentivirus with N-terminal epitope tagging and FACS validation. |
Live TMEM30A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The investigation of TMEM30A as a therapeutic target is accelerating at the intersection of lipid metabolism and immuno-oncology. As the essential β-subunit of P4-ATPase lipid flippases, TMEM30A maintains phospholipid asymmetry by confining phosphatidylserine (PS) to the inner membrane leaflet. Inhibiting TMEM30A forces PS exposure on the outer membrane of tumor cells, generating a potent "eat me" signal for macrophages. First-generation phagocytosis checkpoints (CD47/SIRPα) have shown clinical promise but also toxicity (e.g., anemia); the next wave targets flippase inhibitors, monoclonal antibodies, and bispecifics to reprogram the tumor microenvironment and overcome drug resistance. Beyond oncology, TMEM30A is emerging as a biomarker and target in metabolic disorders (e.g., NASH), lipid transport dysregulation, and as a prognostic indicator in gastric and breast cancers. Current R&D pivots from diagnostic applications toward functional inhibition, with combination strategies involving immune checkpoint modulation and metabolic pathway interference.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies | Early-stage biotechs, academic spin-offs | Solid tumors, hematological malignancies | Cell-based binding assay (need lentivirus for stable expression). |
| Bispecifics (e.g., TMEM30A x CD47) | Discovery-stage innovators | Refractory cancers | Heterodimer validation (need high-purity extracellular domains). |
| ADC (Antibody-Drug Conjugate) | Emerging biotech & academic labs | Gastric cancer, breast cancer | Internalization assay requiring native 7-TM conformation; lentivirus-based stable cell lines essential for accurate trafficking studies. |
| Targeted Degraders (PROTACs) | Preclinical pipelines | Chemo-resistant tumors | Degradation tracking (need sequence verified antibodies & siRNA). |
| Small Molecule Inhibitor | Discovery programs | NASH, lipid metabolism disorders | Cell-based flippase activity assays; co-expression systems with ATP11A for functional readouts. |
| RNA Therapeutics (siRNA / ASO) | Academic / translational labs | Tumor sensitization | Knockdown specificity vs. TMEM30B paralog; validated siRNA controls for selectivity confirmation. |
Note: All product links direct to TarMart catalog pages for ordering or further inquiry.